Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Brace Pharma Capital is a venture capital firm established by EMS S/A, the largest pharmaceutical company in Brazil, alongside high net worth biotech investors. Founded to address significant gaps in treatment options, the firm focuses on innovative therapies for diseases with high unmet medical needs. The organization is headquartered in Atlanta, Georgia, and operates globally, investing in companies that develop life-changing treatments.
Currently, Brace Pharma Capital manages a portfolio of 10 companies, all engaged in pioneering therapeutic solutions across various health conditions. The firm’s investment strategy is deeply rooted in the belief that addressing unmet medical needs can lead to substantial advancements in patient care and outcomes.
Brace Pharma Capital invests primarily in the biotechnology and pharmaceutical sectors, targeting innovative therapies that address diseases with significant unmet medical needs. The firm is particularly interested in life-changing treatments that offer new solutions for health conditions lacking effective therapies. Their investment strategy encompasses a global approach, allowing them to identify and support promising startups across various regions.
The firm typically invests in early to growth-stage companies, providing capital to help them advance their research and development efforts. Brace Pharma Capital seeks founders who demonstrate a strong commitment to their mission and possess a clear vision for their innovations. They prefer to engage in collaborative partnerships that enhance the potential for success in the biotech space.
Brace Pharma Capital's portfolio includes a diverse range of companies focused on developing innovative therapies:
This portfolio reflects Brace Pharma Capital's commitment to supporting companies that are at the forefront of medical innovation, particularly in areas where treatment options are limited.
Daniel E. Salazar, Ph.D.: Vice President of Clinical & Regulatory. Dr. Salazar brings extensive experience in clinical development and regulatory affairs, having worked with various biotech firms prior to joining Brace Pharma Capital.
Todd Brady: Director of Finance & Investments. Brady has a strong background in finance and investment management, with a focus on the biotech sector, making him a valuable asset to the firm.
To pitch Brace Pharma Capital, founders should send an email to info@bracepharma.com with a detailed pitch deck. The deck should include information on the innovation, market opportunity, and team background. Response times may vary, but a prompt and professional approach is recommended.
As of October 2023, Brace Pharma Capital continues to expand its portfolio, focusing on innovative therapies in the biotech sector. The firm has recently made investments in several promising companies, although specific details on these transactions have not been disclosed.
Brace Pharma Capital remains committed to its mission of addressing unmet medical needs through strategic investments in life-changing treatments.
What are Brace Pharma Capital's investment criteria?
Brace Pharma Capital focuses on innovative therapies that address significant unmet medical needs, particularly in the biotech and pharmaceutical sectors. They seek companies developing life-changing treatments.
How can I pitch to Brace Pharma Capital?
Founders can reach out via email at info@bracepharma.com. A well-prepared pitch deck that outlines the innovation, market need, and team background is recommended.
What makes Brace Pharma Capital different from other investors?
The firm is uniquely positioned due to its backing by EMS S/A, Brazil's largest pharmaceutical company, which provides extensive industry knowledge and resources.
What is the geographic scope of Brace Pharma Capital's investments?
Brace Pharma Capital invests globally, focusing on biotech and healthcare companies that are developing innovative therapies.
What is the typical check size for investments?
While specific check sizes are not disclosed, Brace Pharma Capital typically invests in early to growth-stage companies, providing the necessary capital to advance their development.
What kind of support can portfolio companies expect?
Brace Pharma Capital offers operational support, strategic guidance, and access to a network of industry experts to help portfolio companies succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.